fluoromisonidazole has been researched along with Local Neoplasm Recurrence in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akasaki, Y; Fukasawa, N; Miyake, K; Murayama, Y; Ogawa, D; Shimoda, M; Suzuki, K; Suzuki, T; Takei, J; Tanaka, T; Yamamoto, Y | 1 |
| Brenner, AJ; Clarke, GD; Floyd, JR; Fox, PT; Huang, S; Hyun, H; Jerabek, PA; Lee, EQ; Michalek, JE; Muzi, M; Reardon, DA; Schmainda, KM; Wen, PY | 1 |
| Ito, YM; Kuge, Y; Nishikawa, Y; Okamoto, S; Onimaru, R; Peng, H; Shiga, T; Shirato, H; Takeuchi, W; Tamaki, N; Tsuchiya, K; Watanabe, S; Yasuda, K | 1 |
| Asaka, T; Hirata, K; Kitagawa, Y; Ohga, N; Sato, J; Satoh, A; Shiga, T; Tamaki, N; Watanabe, S | 1 |
| Baumann, M; Bergmann, R; Beuthien-Baumann, B; Brüchner, K; Hessel, F; Kotzerke, J; Krause, M; Mosch, B; Schütze, C; Steinbach, J; Thames, H; Yaromina, A; Zips, D | 1 |
| Chen, YL; Cheney, MD; DeLaney, TF; Depauw, N; Grosu, AL; Hornicek, FJ; Lim, R; Schwab, JH; Shih, HA; Trofimov, AV; Winrich, BK | 1 |
| Galoforo, S; Grills, IS; Kane, JL; Krueger, SA; Marples, B; Wilson, GD; Wobb, J | 1 |
| Hirata, K; Houkin, K; Ishi, Y; Kobayashi, H; Kobayashi, K; Motegi, H; Shiga, T; Tamaki, N; Terasaka, S; Toyonaga, T; Yamaguchi, S | 1 |
| Clemenceau, S; Ferrand, R; Feuvret, L; George, B; Habrand, JL; Kerrou, K; Lot, G; Mammar, H; Mazure, N; Mokhtari, K; Nataf, V; Polivka, M; Pontvert, D; Pouysségur, J; Talbot, JN | 1 |
| Bares, R; Dittmann, H; Eschmann, SM; Machulla, HJ; Paulsen, F; Reimold, M; Reischl, G; Welz, S | 1 |
3 trial(s) available for fluoromisonidazole and Local Neoplasm Recurrence
| Article | Year |
|---|---|
[18F]-Fluoromisonidazole positron emission tomography/computed tomography visualization of tumor hypoxia in patients with chordoma of the mobile and sacrococcygeal spine.
Topics: Adult; Aged; Cell Hypoxia; Chordoma; Feasibility Studies; Female; Humans; Male; Middle Aged; Misonidazole; Multimodal Imaging; Neoplasm Recurrence, Local; Photons; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Proton Therapy; Radiopharmaceuticals; Radiotherapy Dosage; Relative Biological Effectiveness; Sacrococcygeal Region; Spinal Neoplasms; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.
Topics: Adult; Cell Hypoxia; Chordoma; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Misonidazole; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Skull Base Neoplasms; Tomography, X-Ray Computed; Young Adult | 2012 |
Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Female; Fluorine Radioisotopes; Germany; Head and Neck Neoplasms; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Misonidazole; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2005 |
7 other study(ies) available for fluoromisonidazole and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Topics: B7-H1 Antigen; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Immunohistochemistry; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Tumor Microenvironment | 2023 |
Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and
Topics: Adult; Aged; Bevacizumab; Biomarkers, Pharmacological; Brain Neoplasms; Cerebral Blood Volume; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Neoplasm Recurrence, Local; Positron-Emission Tomography; Progression-Free Survival; Tumor Hypoxia; Young Adult | 2021 |
Local relapse of nasopharyngeal cancer and Voxel-based analysis of FMISO uptake using PET with semiconductor detectors.
Topics: Adult; Aged; Carcinoma; Female; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Misonidazole; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Intensity-Modulated | 2017 |
Hypoxic volume evaluated by
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Misonidazole; Mouth Neoplasms; Neck Dissection; Neoplasm Grading; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate; Treatment Outcome; Tumor Hypoxia | 2018 |
Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Dose-Response Relationship, Radiation; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Mice; Mice, Nude; Misonidazole; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radionuclide Imaging; Radiopharmaceuticals; Random Allocation; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2014 |
The Effects of Pulsed Radiation Therapy on Tumor Oxygenation in 2 Murine Models of Head and Neck Squamous Cell Carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Coloring Agents; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Heterografts; Mice; Mice, Nude; Misonidazole; Neoplasm Recurrence, Local; Nitroimidazoles; Oxygen Consumption; Positron-Emission Tomography; Radiopharmaceuticals; Squamous Cell Carcinoma of Head and Neck; Tumor Burden | 2015 |
Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Glioma; Humans; Magnetic Resonance Imaging; Middle Aged; Misonidazole; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2016 |